Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 9/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435045 | 1.00 | CYP11B1 (0.36) | CYP11B1CYP11B2ARTRPV4KIF11 | |
| SCHEMBL9314066 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2ARTRPV4KIF11 | |
| SCHEMBL9581295 | 0.79 | AR (0.35) | CYP11B1CYP11B2ARKIF11CES2 | |
| SCHEMBL9581992 | 0.79 | ADRB2 (0.41) | CYP11B1CYP11B2ARKIF11CES2 | |
| SCHEMBL130429 | 0.79 | AR (0.37) | CYP11B1CYP11B2ARKIF11RIPK1 | |
| SCHEMBL9464895 | 0.79 | CES2 (0.37) | CES2RIPK1 | |
| SCHEMBL31195171 | 0.77 | AR (0.42) | CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL9465161 | 0.77 | AR (0.42) | CYP11B1CYP11B2ARTRPV4 | |
| SCHEMBL9730417 | 0.75 | AR (0.39) | CYP11B1CYP11B2ARTRPV4KIF11 | |
| SCHEMBL21455387 | 0.75 | TRPV4 (0.39) | CYP11B1CYP11B2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0398499-A2 | Insecticides | ZENECA LIMITED (GB) | 1990-11-22 | — | — | EP | claimed |
| EP-4558492-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-0553119-A1 | HETEROCYCLIC COMPOUNDS | ZENECA LIMITED (GB) | 1993-08-04 | — | — | EP | disclosed |
| US-5196593-A | HALOGENATED TRIFLUOROMETHYLBENZENES | OCCIDENTAL CHEMICAL CORPORATION (US) | 1993-03-23 | — | — | US | disclosed |
| US-5187176-A | 1-PHENYL SUBSTITUTED PYRIMIDONE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-16 | — | — | US | disclosed |
| WO-1992006964-A1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-04-30 | — | — | WO | disclosed |
| US-5109004-A | Cyano phenyl-substituted with heterocylic compound; insecticides, miticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-04-28 | — | — | US | disclosed |
| US-5079251-A | Insecticides, pesticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-07 | — | — | US | disclosed |
| EP-0408196-A2 | Pyrazinone derivatives as insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-16 | — | — | EP | disclosed |
| EP-0398499-A2 | Insecticides | ZENECA LIMITED (GB) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | CYP11B1 658/4885CYP11B2 725/4885AR 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.